Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07132433
ABSTRACT:
The present invention is directed to use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug depicted as Formula II, wherein R is C1-20alkyl, in treating patients for behavioral or psychological symptoms associated with Alzheimer's disease, Lewy body dementia or Parkinson's disease.
REFERENCES:
patent: 4783471 (1988-11-01), Carr
patent: 4877798 (1989-10-01), Sorensen
patent: 4908369 (1990-03-01), Schlecter et al.
patent: 4912117 (1990-03-01), Carr et al.
patent: 5021428 (1991-06-01), Carr et al.
patent: 5106855 (1992-04-01), McLees
patent: 5134149 (1992-07-01), Carr et al.
patent: 5169096 (1992-12-01), Carr et al.
patent: 5561144 (1996-10-01), Carr et al.
patent: 5618824 (1997-04-01), Schmidt et al.
patent: 5700812 (1997-12-01), Carr et al.
patent: 5700813 (1997-12-01), Carr et al.
patent: 5721249 (1998-02-01), Carr et al.
patent: 6004980 (1999-12-01), Carr et al.
patent: 6028083 (2000-02-01), Carr et al.
patent: 6063793 (2000-05-01), Carr et al.
patent: 6455526 (2002-09-01), Kohn et al.
patent: 0796619 (1997-09-01), None
patent: 99/20315 (1999-04-01), None
patent: WO 00/12090 (2000-03-01), None
Carlos H. Rojas-Fernandez et al., Dementia with Lewy Bodies: Review and Pharmacotherapeutic Implications, Pharmacotherapy (1999, pp. 795-803, vol. 19, No. 7).
Carlsson et al, J. Neural Transm., (1999, vol. 106, pp. 123-129).
Clive Ballard et al., Psychiatric Morbidity in Dementia With Lewy Bodies: A Prospective Clinical and Neuropathological Comparative Study with Alzheimer's Disease, Am J. Psychiatry (1999, pp. 1039-1045, vol. 156, No. 7).
I. G. McKeith et al., What are the relations between Lewy body disease and AD?, J. Neural Transm (1998, pp. 107-116, vol. 54).
John H. Kehne et al., Preclinical Characterization of the Potential of the Putative Atypical Antipsychotic MDL 100,907 as a Potent 5HT2a Antagonist with a Favorable CNS Safety Profile, Journal of Pharmacology and Experimental Therapeutic (1996, pp. 968-981, vol. 277).
Hitchcock Janice M.
Scheyer Richard D.
Sorensen Stephen M.
Aventis Pharmaceuticals Inc.
Gupta Balaram
Spivack Phyllis G.
LandOfFree
Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3637037